Company profile for Kardigan

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Kardigan is a heart health company dedicated to making cardiovascular disease preventable, curable, and no longer the leading cause of death worldwide. By developing multiple targeted treatments in parallel, we aim to bring patients closer to the cures they deserve. Our cutting-edge discovery and translational research platform, combined with a pipeline of late-stage candidates and an industry-leading team, drives our relentle...
Kardigan is a heart health company dedicated to making cardiovascular disease preventable, curable, and no longer the leading cause of death worldwide. By developing multiple targeted treatments in parallel, we aim to bring patients closer to the cures they deserve. Our cutting-edge discovery and translational research platform, combined with a pipeline of late-stage candidates and an industry-leading team, drives our relentless pursuit to move beyond symptom management toward functional cures.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
131 Oyster Point Blvd. Second Floor South San Francisco, CA 94080
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251107785043/en/Kardigan-Presents-Positive-Phase-2-Data-on-Ataciguat-in-Patients-With-Moderate-Calcific-Aortic-Valve-Stenosis-at-American-Heart-Association-Scientific-Sessions-2025

BUSINESSWIRE
07 Nov 2025

https://www.businesswire.com/news/home/20251014696507/en/Kardigan-Raises-%24254-Million-Series-B-to-Advance-Late-Stage-Portfolio-of-Personalized-Cardiovascular-Medicines

BUSINESSWIRE
14 Oct 2025

https://www.fiercebiotech.com/biotech/kardigan-fashions-254m-series-b-spin-late-stage-cardio-assets-through-clinic

FIERCE BIOTECH
14 Oct 2025

https://www.businesswire.com/news/home/20250929918876/en/Kardigan-Announces-Presentation-of-Positive-Phase-2a-Data-for-Danicamtiv-in-Patients-with-Dilated-Cardiomyopathy-at-HFSA-Annual-Scientific-Meeting-2025

BUSINESSWIRE
29 Sep 2025

https://www.businesswire.com/news/home/20250925785986/en/Kardigan-Advances-Late-Stage-Portfolio-of-Personalized-Cardiovascular-Medicines-in-Dilated-Cardiomyopathy-Acute-Severe-Hypertension-and-Calcific-Aortic-Valve-Stenosis

BUSINESSWIRE
25 Sep 2025

https://www.businesswire.com/news/home/20250327713680/en/Kardigan-Acquires-Prolaio-to-Create-a-Pioneering-Heart-Health-Company-with-One-of-a-Kind-Integrated-Cardiovascular-Data-and-Therapeutics-Platform

BUSINESSWIRE
27 Mar 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty